Big Pharma sues Canada for attempting to lower price of $700k drug course that turns hospitals into slave plantations
by: Jonathan Benson
NaturalNews.com
Wednesday, December 02, 2015
Government officials in Canada who are trying to stop a U.S.-based pharmaceutical firm from bilking patients with rare blood disorders out of hundreds of thousands of dollars annually, have found themselves at the center of a major international lawsuit.
Alexion Pharmaceuticals of Cheshire, Connecticut, is attempting to sue the Canadian government for trying to force down the prices of its Soliris (eculizumab) drug for paroxysmal nocturnal hemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS), which costs nearly $700,000 annually per patient with one or both of these diseases.
Soliris is the only drug currently produced by Alexion, and its cost has remained stagnant for the roughly six years it’s been on the market. The Canadian health care system is reportedly tired of shelling out tens of millions of dollars per patient to cover the outrageous costs associated with the prescription of Soliris, and is thus working towards a lower cost solution.
But Alexion is adamantly opposed to decreasing the price of Soliris, which has earned the company some $6 billion since it was first brought to the commercial market. And for folks like Marie-Eve Chainey of Ottawa, this anti-patient resistance could spell the end of her treatment protocol.
“What do I do?” asked Chainey, speaking to Canada’s CBC News about Soliris, which is currently the world’s most expensive pharmaceutical drug.
The Rest…HERE
